electroCore (DB:43) - Cotización, noticias y análisis

Resumen de acción 43

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

Acerca de la empresa

43 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Cotiza un 95.2% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los ingresos de 34.57%

Análisis de riesgos

Acciones altamente ilíquidas

No tiene una capitalización de mercado significativa (€32M)

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de electroCore, Inc.

Geratherm Medical

XTRA:GME

€22.8m

NanoRepro

XTRA:NN6

€22.2m

aap Implantate

XTRA:AAQ1

€13.6m

MagForce

XTRA:MF6

€3.6m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for electroCore
Historical stock prices
Current Share Price	US$3.67
52 Week High	US$9.96
52 Week Low	US$2.50
Beta	1.21
1 Month Change	0%
3 Month Change	-13.44%
1 Year Change	-15.30%
3 Year Change	-70.37%
5 Year Change	n/a
Change since IPO	-97.98%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	43	DE Medical Equipment	Mercado DE
7D	0%	2.8%	0.4%
1Y	-15.3%	1.3%	4.4%

Rentabilidad vs. Industria: 43E0 obtuvo unos resultados inferiores a los del sector German Medical Equipment , que el año pasado arrojó un rendimiento del -13.6%.

Rentabilidad vs. Mercado: 43E0 obtuvo unos resultados inferiores a los del mercado German, que fue del -0.3% el año pasado.

Volatilidad de los precios

Is 43's price volatile compared to industry and market?
43 volatility
43 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	4.5%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.2%
10% least volatile stocks in DE Market	2.5%

Precio estable de las acciones: El precio de las acciones de 43E0 ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de 43E0 en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2005	62	Dan Goldberger	www.electrocore.com

Resumen de fundamentos de electroCore, Inc.

¿Cómo se comparan los beneficios e ingresos de electroCore con su capitalización de mercado?
Estadísticas fundamentales de 43
Capitalización bursátil	€29.25m
Beneficios(TTM)	-€20.66m
Ingresos (TTM)	€8.72m

3.4x

Ratio precio-ventas (PS)

-1.4x

Ratio precio-beneficio (PE)

¿Está 43 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 43
Ingresos	US$9.47m
Coste de los ingresos	US$1.48m
Beneficio bruto	US$8.00m
Otros gastos	US$30.45m
Beneficios	-US$22.45m

Últimos beneficios comunicados

Mar 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-4.73
Margen bruto	84.43%
Margen de beneficio neto	-236.96%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado 43 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 43

Recompensas

Análisis de riesgos

Competidores de electroCore, Inc.

XTRA:GME

€22.8m

XTRA:NN6

€22.2m

XTRA:AAQ1

€13.6m

XTRA:MF6

€3.6m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

electroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million.

electroCore, Inc. announced a financing transaction

electroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and Compliance

electroCore, Inc. to Report Q1, 2024 Results on May 08, 2024

electroCore, Inc. Announces Results of Truvaga Plus Consumer Study

electroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness

Recent updates

electroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million.

electroCore, Inc. announced a financing transaction

electroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and Compliance

electroCore, Inc. to Report Q1, 2024 Results on May 08, 2024

electroCore, Inc. Announces Results of Truvaga Plus Consumer Study

electroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness

electroCore, Inc. to Report Q4, 2023 Results on Mar 13, 2024

electroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the Board

Electrocore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation (Nvns) for Treatment of Symptoms of Gastroparesis

electroCore, Inc. to Report Q3, 2023 Results on Nov 08, 2023

electroCore, Inc. Announces the Publication of Two Peer Reviewed Publication of Two Peer Reviewed Publications Supporting the Use of Gammacore ( Non-Invasive Vagus Nerve Stimulation; nVNS) in Patients with Post Traumatic Stress Disorder

electroCore, Inc. Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering

electroCore, Inc. Reiterates Revenue Guidance for the Year 2023

electroCore, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Electrocore Provides Earnings Guidance for the Second Quarter and Full Fiscal Year 2023

electroCore, Inc., Annual General Meeting, Aug 04, 2023

electroCore, Inc. Reiterates Revenue Guidance for the Year Ending December 31, 2023

electroCore, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2022

electroCore Receives a Determination Letter from Nasdaq Regarding Minimum Bid Price

electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga

electroCore, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

electroCore, Inc. to Report Q3, 2022 Results on Nov 03, 2022

electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

electroCore, Inc., Annual General Meeting, Dec 02, 2022

electroCore, Inc. Announces Publication of a Peer Reviewed Manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use Disorder

electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

electroCore, Inc. to Report Q2, 2022 Results on Aug 04, 2022

electroCore, Inc. Provides Preliminary Unaudited Earnings Guidance for the Second Quarter of 2022

Electrocore, Inc. Announces Study of Gammacore Sapphire™ for the Treatment of Post-Covid Syndrome

electroCore Announces Listing Transfer to the Nasdaq Capital Market

Co-Founder recently bought €53k worth of stock

Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

First quarter 2022 earnings released: US$0.079 loss per share (vs US$0.11 loss in 1Q 2021)

electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2022

High number of new directors

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

electroCore, Inc. Provides Unaudited Preliminary Revenue Guidance for the First Quarter of 2022

High number of new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

electroCore, Inc. to Report Q4, 2021 Results on Mar 10, 2022

electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus

electroCore, Inc. Provides Revenue Guidance for the Full Year of 2021

electroCore, Inc. Announces Publication of Premium II Trial of Gammacore (Non-Invasive Vagus Nerve Stimulation; nVNS) for the Prevention of Migraine

Third quarter 2021 earnings released: US$0.057 loss per share (vs US$0.10 loss in 3Q 2020)

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua

Second quarter 2021 earnings released: US$0.06 loss per share (vs US$0.13 loss in 2Q 2020)

electroCore, Inc. Announces Revenue Guidance for the Second Quarter of 2021

electroCore, Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

electroCore, Inc. Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson’S Disease Patients

electroCore, Inc. Develops Non-Drug and Non-Invasive Alternative to Pharmaceuticals That Safely and Effectively Stimulates the Vagus Nerve to Communicate with the Brain and Help Optimize the Body’s Own Ability to Control Problems Impacting Its Health

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.27 loss in 1Q 2020)

electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2021

electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders

ElectroCore, Inc. Provides Revenue Guidance for the First Quarter of 2020

Full year 2020 earnings released: US$0.60 loss per share (vs US$1.54 loss in FY 2019)

electroCore, Inc. to Report Q4, 2020 Results on Mar 11, 2021

electroCore, Inc. Announces Exclusive Distribution Agreement with Medistar2 PTY Limited Following Regulatory Approval in Australia

Non-Invasive Vagus Nerve Stimulation (Nvns) Enters New Stage of Covid-19 Research of electrocore, Inc